- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03037398
Closed Loop Programming Evaluation Using External Responses for Deep Brain Stimulation (CLOVER)
April 9, 2024 updated by: Boston Scientific Corporation
The objective of this study is to evaluate the performance of novel DBS programming methods compared to traditional programming methods.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Heleen Scholtes
- Phone Number: 855-213-9890
- Email: BSNClinicalTrials@bsci.com
Study Contact Backup
- Name: Diane Keesey
- Phone Number: 855-213-9890
- Email: BSNClinicalTrials@bsci.com
Study Locations
-
-
-
Berlin, Germany
- Suspended
- University Berlin, Charite Virchow Standort, Wedding
-
Hamburg, Germany
- Recruiting
- Universitaetsklinik Eppendorf
-
Contact:
- Boston Scientific Clinical Research Manager
- Phone Number: 855-213-9890
- Email: BSNClinicalTrials@bsci.com
-
Kiel, Germany
- Recruiting
- Universitätsklinikum Campus Kiel
-
Contact:
- Boston Scientific Clinical Research Manager
- Phone Number: 855-213-9890
- Email: BSNClinicalTrials@bsci.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Implanted bilaterally in STN or GPi with a Vercise™ DBS system for Parkinson's disease, including directional leads, for at least four months and programming optimized according to standard of care with no changes to electrode configuration of primary settings for at least four weeks.
- Able to understand the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed.
- Be at least 18 years of age.
- Device must have been implanted on label or must be on label by the time the subject gets enrolled.
Key Exclusion Criteria:
- Any significant psychiatric problems, including unrelated clinically significant depression as determined by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Novel Arm
Programming completed by a novel method
|
|
Other: Standard of Care Arm
Programming completed as Standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in time to program between the two arms at Programming Visit
Time Frame: at least four months post implant
|
at least four months post implant
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Natalie Bloom Lyons, Boston Scientific Neuromodulation Corporation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 11, 2017
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
January 12, 2017
First Submitted That Met QC Criteria
January 27, 2017
First Posted (Estimated)
January 31, 2017
Study Record Updates
Last Update Posted (Actual)
April 10, 2024
Last Update Submitted That Met QC Criteria
April 9, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A4063
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Vercise Deep Brain Stimulation System
-
Boston Scientific CorporationCompletedParkinson's DiseaseUnited States
-
University Hospital FreiburgBoston Scientific CorporationCompleted
-
University Hospital FreiburgBoston Scientific CorporationRecruitingTreatment-resistant DepressionGermany, France
-
Boston Scientific CorporationRecruitingParkinson's DiseaseUnited States, Korea, Republic of, Italy, Poland, Spain, France, Germany, Israel, United Kingdom, Canada, Argentina, Austria, Belgium, Hungary
-
Mustafa Kemal UniversityUnknown
-
Boston Scientific CorporationRecruitingDystoniaGermany, United Kingdom, Italy, Belgium, Hungary, Israel, Netherlands, Poland, Russian Federation, Spain, Korea, Republic of
-
University of California, DavisRecruiting
-
Wuerzburg University HospitalUnknownParkinson Disease | DementiaGermany
-
Casey H. Halpern, M.D.Stanford UniversityRecruiting
-
University of Sao Paulo General HospitalRecruitingParkinson Disease | Mild Cognitive ImpairmentBrazil